An Exploratory Single-arm Study to Evaluate the Effect of Pertuzumab in Combination With Herceptin on Response Rate in Patients With HER2-positive Metastatic Breast Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Objective response according to Response Evaluation Criteria in Solid Tumors (RECIST)
24 weeks
No
Clinical Trials
Study Chair
Hoffmann-La Roche
Italy: Ministry of Health
BO17929
NCT01674062
May 2006
December 2016
Name | Location |
---|